Clinical Trial Detail

NCT ID NCT03173560
Title Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eisai Inc.

clear cell renal cell carcinoma


Everolimus + Lenvatinib

Age Groups: adult senior

No variant requirements are available.